LCNDG Rapid Review: Tegafur, gimeracil, and oteracil (known as S1)for first-line palliative treatment of advanced gastric cancer

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews The evidence to support tegafur/gimeracil/oteracil plus cisplatin for this indication derives from one pivotal phase III multicentre, randomised, open-label study to compare overall survival (OS) for cisplatin plus tegafur/gimeracil/oteracil (CS) with cisplatin plus 5-fluorouracil iv (CF) in adult patients with advanced gastric cancer, previously untreated with chemotherapy (FLAGS study). It is important to note that the comparator used in the FLAGS study (CF) is not relevant for UK practice, where patients would normally receive EOX or ECX.   The median follow-up was 18.3 months (range 12.1-31.8 months). The final primary analysis of survival was conducted in the full analysis set, which consisted of all patients who were dosed with study drug (n=521 for CS; n=508 for CF) and included deaths up to 12 months after the last patient was randomly assigned. The median survival of patients in the CS arm was 8.6 months compared with 7.9 months for patients in the CF arm ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news